



NRG NCORP General Session

PIs

Deborah Watkins Bruner, RN, PhD, FAAN

 @DeborahWBruner1

and

Joan Walker, MD

Associate PI

Lisa Kachnic, MD, FASTRO

Open NRG NCORP Trials

Study No	Disease Site	Description	Date Activated	Target Accrual	Total Accrual	NCORP Accrual (%)	Expected Closure Date
NRG CC005	GI	FORTE – Five- or Ten-Year Colonoscopy for 1-2 Non-advanced Adenomatous Polyps	10/6/21	9500	768	81%	June 2033
NRG CC008	Ovarian	Non-randomized prospective trial comparing non-inferiority of Salpingectomy to salpingo-Oophorectomy to Reduce the risk of Ovarian Ca among <i>BRCA1</i> carriers (SOROCK)	6/23/20	2262	363	20%	February 2033
NRG CC009	Brain	SRS vs. HA-WBRT for 10 or Fewer Brain Metastases from Small Cell Lung Cancer	2/24/21	200	57	45%	September 2028
NRG CC0010	Endo	Ph III Trial of the Impact of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer	9/19/22	428	26	39%	January 2033

Developing NRG NCORP Trials

Study No.	Protocol/Concept	Comments
NRG-CC0011 Diane Von Ah, PhD	Cognitive Training for Cancer-related Cognitive Impairment: A Multi-Center Randomized Controlled Trial	Anticipated activation late Q4 2023
NRG-CC012CD Alla Sikorski, PhD, Terry Badger, PhD; Tracy Crane, PhD	Managing symptoms and psychological distress during oral anti-cancer treatment	Protocol submitted to DCP
NRG-CC2137CD Kathryn Schmitz, PhD; Jennifer Trilk, PhD	Exercise is Medicine in Medical Oncology	R01 resubmission July 2023
NRG-CC2324 David Brizel, MD; Sue Yom, MD	Prospective single arm, Ph II trial of concurrent chemoRT with the radioprotector BMX-001 in patients with HNSCC receiving concurrent chemoRT	Concept reviewed by DCP 6/20/23, revisions required
NRG-CC2313 Noël Arring, DNP, PhD, RN	American Ginseng as a Treatment for Cancer-Related Fatigue	R01 submission October 2023
NRG-CC2325 Jiayi Huang, MD	Randomized phase 3 study comparing TMPRT vs standard RT with TMZ for elderly patients with newly diagnosed MGMT-unmethylated glioblastoma to prolong symptom deterioration-free survival	Concept submitted to DCP for July 25, 2023 review
NRG-CC2327 Erin F Gillespie, MD MPH	Radiation therapy for high-risk asymptomatic bone metastases: A pragmatic multicenter randomized phase III clinical trial	Pending concept submission to DCP

NCORP Concept Review

Phase II randomized, double blind, placebo-controlled trial of Avmacol to evaluate rates of second primary tumor formation in patients with a history of tobacco associated head and neck squamous cell carcinoma (HNSCC) – Sid Sheth, MD	NCORP concept review July 21, 2023
WRITE Symptoms 4 Self-Management: A Hybrid Type Effectiveness Trial of the Self-Directed WRITE Symptoms Intervention for Survivors Living with Advanced or Recurrent Gynecologic Cancers – Heidi Donovan, PhD, RN	NCORP concept review July 21, 2023; anticipate R01 submission September 2023

NRG NCORP RESOURCES





New Process for NCORP Pilot Projects

NRG NCORP will host a workshop during the NRG winter meeting, February 2024.

Workshop goal: to prepare investigators to develop committee aim-aligned NCORP pilot projects that would potentially lead to a larger NCORP concept.

- Application requires investigators to submit a two-page LOI form due November 3, 2023.
- NCORP committee chairs will review LOIs and select those best aligned with the committee goals, NCORP priorities, and deemed most feasible for future Phase II – III NCORP concepts.
- Selected investigators will be invited to attend a workshop during the winter NRG meeting.

The LOI process is a prerequisite for pilot grant application submission for 2024.

- The request for funding application (RFA) for NCORP pilot projects will be released in Spring 2024.
- While workshop selection and enrollment does not guarantee pilot funding, the activities are designed to facilitate successful submissions.

NRG Health Equity Fellowship Program

The Health Equity Fellowship Program outlines three strategic, high-level goals to provide a broader perspective in clinical trials research:

1. Increase representation from diverse backgrounds with emphasis on recruitment of researchers from historically underrepresented groups (HUGs), as defined by the NIH.
2. Mentor selected early-stage NRG Oncology investigators in clinical trials education and training. The program provides networking opportunities and pathways to leadership for HUGs.
3. Develop successful clinical trials scientists who can compete in grant writing opportunities.

Read more about this opportunity at:

<https://www.nrgoncology.org/Health-Equity-Fellowship>

New applications will be accepted Fall 2023

Specimen (S) and Patient (P) Summary

Trial	Ascites	Buffy Coat	CSF	FFPE	Isocode Card	OCT	Plasma	Peritoneal Fluid	RBCs	Serum	Snap Frozen	Stool	ThinPrep	Urine	Whole Blood
GOG-0199	17 (S) 17 (P)			170 (S) 32 (P)		4,704 (S)	57,400 (S) 2,653 (P)	1,193 (S) 1,091 (P)		57,083 (S)	351 (S) 99 (P)				
GOG-0207				2,860 (S) 127 (P)						955 (S) 116 (P)			34 (S) 2 (P)		
GOG-0214				803 (S) 64 (P)		132 (S) 60 (P)	541 (S) 63 (P)			578 (S) 63 (P)					
GOG-0215				0 (S) 0 (P)			126 (S) 8 (P)	1 (S) 1 (P)		154 (S) 8 (P)	49 (S) 13 (P)				
GOG-0224				85 (S) 9 (P)			70 (S) 8 (P)			35 (S) 7 (P)					
GOG-0225							11,683 (S) 985 (P)			4,937 (S) 867 (P)					4,685 (S) 765 (P)
GOG-0237				7,394 (S) 710 (P)									594 (S) 581 (P)		
GOG-0273							1,602 (S) 189 (P)								
NRG-CC001										3870 (S) 317 (P)					1184 (S) 288 (P)
NRG-CC003										3423 (S) 219 (P)					652 (S) 186 (P)
NRG-CC005		271 (S) 135 (P)					500 (S) 134 (P)					935 (S) 468 (P)			
NRG-CC008				39 (S) 4 (P)			1,666 (S) 270 (P)			1,629 (S) 269 (P)					366 (S) 270 (P)
NRG-CC009										136 (S) 16 (P)					
NSABP-B-43				3,089 (S) 1,850 (P)											
NSABP-P-1		23,601 (S) unknown		11,432 (S) unknown			49,617 (S) unknown								
NSABP-P-2		77,074 (S) unknown		16,197 (S) unknown	19,810 (S) unknown (P)		77,467 (S) unknown		38,590 (S) unknown						
NSABP-P-5		322 (S) 322 (P)		3,059 (S) 339 (P)						1,935 (S) 332 (P)					(S) (P)
RTOG-0614		679 (S) 181 (P)	10 (S)				1216 (S) 250 (P)			1530 (S) 268 (P)			701 (S)	1 (S) 1 (P)	
RTOG-0631		12 (S) 5 (P)					1387 (S) 158 (P)			1311 (S) 158 (P)			426 (S)	774 (S) 150 (P)	
RTOG-0831		9 (S) 18 (P)					577 (S) 111 (P)			619 (S) 110 (P)				485 (S) 101 (P)	
RTOG-0925				891 (S) 74 (P)			223 (S) 40 (P)						84 (S) 43 (P)	226 (S) 41 (P)	
RTOG-0933		1 (S) 1 (P)					591 (S) 67 (P)			663 (S) 67 (P)				217 (S) 60 (P)	
RTOG-1203				1312 (S) 208 (P)			3968 (S) 209 (P)			3766 (S) 209 (P)				1251 (S) 203 (P)	

NRG NCORP

Biospecimens Available!

Tamoxifen Breast Cancer Prevention Trial (BCPT): NSABP P-1 Study

enrolled 13,388 pre-and postmenopausal women aged 35 years and older who were at an increased risk for breast cancer to receive tamoxifen or placebo for 5 years (1992 – 1997)

Study of Tamoxifen and Raloxifene (STAR) NSABP P-2 Study

enrolled 19,490 women at least 35 years of age and postmenopausal at increased risk for breast cancer to receive tamoxifen or raloxifene for 5 years (1999 - 2004)

Committee Transitions

CPC Committee



Debra Barton, PhD, RN
Research Professor
University of Tennessee
School of Nursing
NRG Oncology
Cancer Control Vice-Chair
August 2019 – July 2023



Tracy Crane, PhD, RDN
Associate Professor
Miller School of Medicine
Co-Leader,
Cancer Control Research Program
University of Miami
NRG Oncology
Cancer Control Vice-Chair
Beginning August 1, 2023

HDR Committee



Chanita Hughes-Halbert, PhD
Professor and Vice Chair of research in the
Department of Population and Public Health
Sciences, Associate Director for Cancer
Equity, Keck School of Medicine of USC
NRG Oncology
Health Disparities Research
Vice-Chair
June 2019 – September 2023

Seeking Vice-Chair, NRG Oncology NCORP Health Disparities Research Committee

June 28, 2023

Application Deadline: August 1, 2023

We are seeking nominations for the position of Vice-Chair of the NRG NCORP Health Disparities Research (HDR) committee. The successful candidate will work closely with the chair, Dr. Jennifer Wenzel and provide support to lead the HDR committee. The overarching goal of NRG HDR is to understand and address health disparities in an effort to reduce the unequal burden of cancer in the United States. Candidates for this position should have a track record of funding and/or publications in successful methods to improve access to clinical trials in historically underserved populations. The candidate should demonstrate a passion to elevate and nurture cancer equity, ensuring that NRG Oncology trials prioritize health and cancer outcomes for all patients, families, and communities. Further, the candidates should have documented achievements in mentorship and a willingness to provide timely consultation to members and liaisons of NRG committees as concepts and protocols are being developed.

NRG Oncology Committee Chairs and Vice-Chairs must be at an NRG Oncology Member Institution and eligible to receive federal funding. Nominal funds from federal grants to offset related effort and travel to NRG Oncology meetings is provided.

Applicants for the position should forward a cover letter addressing your specific interests and qualifications for the role as listed above, as well as your NIH biosketch to committee-nominations@nrgoncology.org. The deadline for the application submission is August 1, 2023. If you have questions about the position, forward those to the same email and we will have an appropriate party get back to you.

Stay Engaged in NRG Oncology



@NRGOnc, @FORTEStudy



@NRGOnc , @FORTEStudy



@NRG Oncology



@NRG Oncology

